GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: The IUPAC descriptor for this compound was obtained from the FDA's list of Orphan Drug Designations and Approvals [1]. It maps to a chemical structure claimed in patent WO2020160054A1, for activity as a Toll-like receptor 7 (TLR7) and/or TLR8 agonist [2]. We suspect that this is CAN1012 (CanWell Pharma), a selective TLR7 agonist, but the structure of CAN1012 has not been formally disclosed.
|
|
|||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| CAN1012 is designed to be delivered intratumourally, and is proposed to induce localised NF-κB activation and significant IFNα release, leading to an antitumour immune response. |